PRevention Using EPA Against coloREctal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions

Colorectal AdenomaColorectal CancerEndoscopic SurgeryEicosapentaenoic AcidGastrointestinal Microbiome

Interventions

DRUG

AMR101

AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks

Trial Locations (1)

Massachusetts General Hospital, Boston

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

lead

Massachusetts General Hospital

OTHER

NCT04216251 - PRevention Using EPA Against coloREctal Cancer | Biotech Hunter | Biotech Hunter